The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone (D-VRd) improved outcomes in patients with newly diagnosed multiple myeloma (MM) compared with VRd
A study presented by Meletios Dimopoulos, MD, of the National and Kapodistrian University of Athens, as part of the SOHO 2025 Annual Meeting,
A phase 1/2 study showed that iberdomide, daratumumab, and dexamethasone (IBERDd) had a manageable safety profile when used in transplant-ineligible, newly diagnosed multiple
Prior studies have shown conflicting outcomes for patients with different follicular lymphoma (FL) grade subtypes. A recent study by Patrizia Mondello, MD, PhD
